FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207788> ?p ?o ?g. }

• W4387207788 endingPage "S171" @default.
• W4387207788 startingPage "S171" @default.
• W4387207788 abstract "Hypofractionated and stereotactic body radiotherapy (SBRT) are increasingly used in the treatment of centrally located, early-stage non-small cell lung cancer (NSCLC), though there are concerns of increased morbidity and mortality in patients with ultracentral tumors (UC). We report on the long-term toxicity of patients with UC lung cancer treated on a prospective randomized clinical trial of SBRT versus conventionally hypofractionated radiotherapy (CRT) for stage I NSCLC (NCT01968941).Patients with UC tumors, defined as those where the planning target volume directly overlaps with the proximal bronchial tree (PBT), were identified from the larger cohort of patients treated on the trial. These patients received either SBRT with 60 Gy in 8 fractions or CRT with 60 Gy in 15 fractions. The primary endpoint of this secondary analysis was development of any grade 3 or higher toxicity defined using CTCAE version 3.0. Secondary endpoints included local control, as well as dosimetric analysis of the PBT, using EQD2 with α/β ratio of 3 to assess the relationship between dose to the PBT and toxicity.Twenty-nine patients were identified with UC tumors; 21 received SBRT and 8 received CRT. Median age was 72 years (range 55-88 years) and 59% were female. Median FEV1 was 1.46L (range 0.64-2.37L). Patients had either T1 (59%) or T2 (41%) lesions, with median tumor size 2.5cm (range 1.1-4.9cm). Most patients had histologically confirmed disease (squamous cell, n = 10; adenocarcinoma, n = 8; radiographically suspicious, n = 11). The median follow-up was 2.9 years (range 0.7-5.2 years). The 3-year local control rate of all patients was 88.3% (95% confidence interval: 75.7-100%). There were 3 patients with late (>3 months) grade 3 toxicity (bronchial stricture, chest pain, and atelectasis) and 1 patient with late grade 5 toxicity (bleeding/hemorrhage), all treated in the SBRT arm. Median EQD2 dose to PBT in patients with grade ≥3 late toxicity compared to the rest of the cohort was: Dmax, 132 vs 129 Gy; D0.1cc, 129 vs 119 Gy; D1cc, 124 vs 80 Gy; and D5cc, 83 vs 41 Gy. Median EQD2 volumetric doses in grade ≥3 patients (compared to the rest) to PBT were: V65 Gy, 9.7 vs 2.2cc; V80 Gy, 7.9 vs 1.1cc; V90 Gy, 6.2 vs 0.4cc; and V100 Gy, 4.8 vs 0.3cc. The single patient with grade 5 toxicity had the highest D5cc (116 Gy) and V100 Gy (7cc) among all patients.Stereotactic radiation with 60 Gy in 8 fractions for UC lung cancer provides good local control but carries an approximately 15-20% rate of late grade ≥3 toxicity. There appears to be a dosimetric association between toxicity and dose to the PBT. It may be more important to minimize volumetric PBT dose rather than maximum point dose to reduce risk of severe late toxicity." @default.
• W4387207788 created "2023-09-30" @default.
• W4387207788 creator A5002547008 @default.
• W4387207788 creator A5007941548 @default.
• W4387207788 creator A5020391612 @default.
• W4387207788 creator A5026555468 @default.
• W4387207788 creator A5035232594 @default.
• W4387207788 creator A5042773636 @default.
• W4387207788 creator A5044329891 @default.
• W4387207788 creator A5044903935 @default.
• W4387207788 creator A5057219088 @default.
• W4387207788 creator A5063012663 @default.
• W4387207788 creator A5064693052 @default.
• W4387207788 creator A5066563261 @default.
• W4387207788 creator A5070388904 @default.
• W4387207788 creator A5072729397 @default.
• W4387207788 creator A5083571210 @default.
• W4387207788 creator A5088432987 @default.
• W4387207788 creator A5091514993 @default.
• W4387207788 date "2023-10-01" @default.
• W4387207788 modified "2023-10-17" @default.
• W4387207788 title "Long-Term Toxicity in Patients Receiving Radiotherapy for Ultracentral Stage I Non-Small Cell Lung Cancer – A Secondary Analysis of the LUSTRE Randomized Trial" @default.
• W4387207788 doi "https://doi.org/10.1016/j.ijrobp.2023.06.636" @default.
• W4387207788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784427" @default.
• W4387207788 hasPublicationYear "2023" @default.
• W4387207788 type Work @default.
• W4387207788 citedByCount "0" @default.
• W4387207788 crossrefType "journal-article" @default.
• W4387207788 hasAuthorship W4387207788A5002547008 @default.
• W4387207788 hasAuthorship W4387207788A5007941548 @default.
• W4387207788 hasAuthorship W4387207788A5020391612 @default.
• W4387207788 hasAuthorship W4387207788A5026555468 @default.
• W4387207788 hasAuthorship W4387207788A5035232594 @default.
• W4387207788 hasAuthorship W4387207788A5042773636 @default.
• W4387207788 hasAuthorship W4387207788A5044329891 @default.
• W4387207788 hasAuthorship W4387207788A5044903935 @default.
• W4387207788 hasAuthorship W4387207788A5057219088 @default.
• W4387207788 hasAuthorship W4387207788A5063012663 @default.
• W4387207788 hasAuthorship W4387207788A5064693052 @default.
• W4387207788 hasAuthorship W4387207788A5066563261 @default.
• W4387207788 hasAuthorship W4387207788A5070388904 @default.
• W4387207788 hasAuthorship W4387207788A5072729397 @default.
• W4387207788 hasAuthorship W4387207788A5083571210 @default.
• W4387207788 hasAuthorship W4387207788A5088432987 @default.
• W4387207788 hasAuthorship W4387207788A5091514993 @default.
• W4387207788 hasConcept C121608353 @default.
• W4387207788 hasConcept C126322002 @default.
• W4387207788 hasConcept C141071460 @default.
• W4387207788 hasConcept C143998085 @default.
• W4387207788 hasConcept C146357865 @default.
• W4387207788 hasConcept C151730666 @default.
• W4387207788 hasConcept C203092338 @default.
• W4387207788 hasConcept C2776256026 @default.
• W4387207788 hasConcept C2780387249 @default.
• W4387207788 hasConcept C2781182431 @default.
• W4387207788 hasConcept C29730261 @default.
• W4387207788 hasConcept C509974204 @default.
• W4387207788 hasConcept C535046627 @default.
• W4387207788 hasConcept C71924100 @default.
• W4387207788 hasConcept C86803240 @default.
• W4387207788 hasConceptScore W4387207788C121608353 @default.
• W4387207788 hasConceptScore W4387207788C126322002 @default.
• W4387207788 hasConceptScore W4387207788C141071460 @default.
• W4387207788 hasConceptScore W4387207788C143998085 @default.
• W4387207788 hasConceptScore W4387207788C146357865 @default.
• W4387207788 hasConceptScore W4387207788C151730666 @default.
• W4387207788 hasConceptScore W4387207788C203092338 @default.
• W4387207788 hasConceptScore W4387207788C2776256026 @default.
• W4387207788 hasConceptScore W4387207788C2780387249 @default.
• W4387207788 hasConceptScore W4387207788C2781182431 @default.
• W4387207788 hasConceptScore W4387207788C29730261 @default.
• W4387207788 hasConceptScore W4387207788C509974204 @default.
• W4387207788 hasConceptScore W4387207788C535046627 @default.
• W4387207788 hasConceptScore W4387207788C71924100 @default.
• W4387207788 hasConceptScore W4387207788C86803240 @default.
• W4387207788 hasIssue "2" @default.
• W4387207788 hasLocation W43872077881 @default.
• W4387207788 hasLocation W43872077882 @default.
• W4387207788 hasOpenAccess W4387207788 @default.
• W4387207788 hasPrimaryLocation W43872077881 @default.
• W4387207788 hasRelatedWork W2003938723 @default.
• W4387207788 hasRelatedWork W2047967234 @default.
• W4387207788 hasRelatedWork W2118496982 @default.
• W4387207788 hasRelatedWork W2403361534 @default.
• W4387207788 hasRelatedWork W2407189953 @default.
• W4387207788 hasRelatedWork W2439875401 @default.
• W4387207788 hasRelatedWork W2465910797 @default.
• W4387207788 hasRelatedWork W3089163820 @default.
• W4387207788 hasRelatedWork W3171615116 @default.
• W4387207788 hasRelatedWork W2525756941 @default.
• W4387207788 hasVolume "117" @default.
• W4387207788 isParatext "false" @default.
• W4387207788 isRetracted "false" @default.
• W4387207788 workType "article" @default.